Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S.

As of June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. carries a market capitalization of 2.64B, placing it among publicly traded companies globally. Its enterprise value stands at 2.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. has 93.41M shares outstanding.

As of June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. trades at a trailing price-to-earnings ratio of 195.55. The price-to-sales ratio is 1.18, and the price-to-book ratio stands at 0.79.

As of June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. trades at an EV/EBITDA multiple of 9.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 54.45 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.21B versus a market cap of 2.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. maintains a current ratio of 3.76, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.82, indicating moderate leverage, while an interest coverage ratio of 6.06 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. posted a return on equity (ROE) of 0.58, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.48, measuring how efficiently the asset base is converted into earnings. The company generates approximately 3.58M in revenue per employee across its workforce of 793.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.98 indicates how many times Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. recorded an income tax benefit of -85.47M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -66.10M and 17.18M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S.'s stock has declined approximately 41.78% over the past 52 weeks. The 50-day moving average sits at 21.65, while the 200-day moving average is 27.15.

Over the twelve months ended June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. generated 2.84B in revenue and converted that into 17.18M in net income, yielding earnings per share of 0.16. EBITDA reached 224.14M, while operating income came in at 78.27M.

As of June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. holds 484.26M in cash and equivalents against 27.91M in total debt, resulting in a net debt position of -461.65M. Total book value stands at 3.36B, with working capital of 1.46B providing operational flexibility.

Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. produced 540.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -220.39M in capital expenditures, free cash flow totaled 319.96M - equivalent to 2.69 per share.

Over the twelve months ended June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. posted a gross margin of 31.20, reflecting its pricing power and cost economics. The operating margin of 2.76 and net profit margin of 0.61 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. paid dividends of 0.22 per share. The dividend payout ratio of 120.20 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.52, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. shareholders.

Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S.'s most recent stock split took place on February 22, 2022 with a 2:7 split ratio.

As of June 30, 2026, Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. has an Altman Z-Score of 3.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.